Structure-activity relationships of 2′,5′-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists

Nucleosides, Nucleotides and Nucleic Acids

Volumn 31, Issue 5, 2012, Pages 432-444

  Wang, Xinning ^a   Tian, Haibin ^b   Lee, Zhenghong ^b   Heston, Warren D W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 , 5 oligoadenylate conjugate; PSMA; Structure activity relationship

Indexed keywords

2 [3 (5 AMINO 1 CARBOXYPENTYL)UREIDO]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 2 [1 [4 [[(4 FLUOROBENZYLAMINO)METHYL]CARBAMOYL]CYCLOHEXYL] 2,5 DIOXOPYRROLIDIN 3 YLSULFANYL]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [2 [1 [4 (6 TERT BUTOXYCARBONYLAMINOHEXYLCARBAMOYL)CYCLOHEXYL] 2,5 DIOXOPYRROLIDIN 3 YLSULFANYL] 1 CARBOXYETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [2 [1 [4 [6 [[2 (6 AMINOPURIN 9 YL) 4 HYDROXY 5 THIOPHOSPHONOOXYMETHYLTETRAHYDROFURAN 3 YLOXY]HYDROXYTHIOPHOSPHORYLOXY]HEXYLCARBAMOYL]CYCLOHEXYLMETHYL] 2,5 DIOXOPYRROLIDIN 3 YLSULFANYL] 1 CARBOXYETHYL]UREIDO]PENTANEDIOIC ACID; 6 [[4 [3 [2 CARBOXY 2 [3 (1,3 DICARBOXYPROPYL)UREIDO]ETHYLSULFANYL] 2,5 DIOXOPYRROLIDIN 1 YL]CYCLOHEXANECARBONYL]AMINO]HEXYL AMMONIUM CHLORIDE; ANTINEOPLASTIC AGENT; OLIGOADENYLIC ACID DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTAGONIST; RBI 1033; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENINE NUCLEOTIDES; ANTIGENS, SURFACE; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; MALE; MOLECULAR IMAGING; NEOPLASM METASTASIS; OLIGORIBONUCLEOTIDES; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859806938     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2012.671988     Document Type: Article

References (32)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Israeli, R.S.; Powell, C.T.; Corr, J.G.; Fair, W.R.; Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54, 1807-1811. (Pubitemid 24116191)
3. Tasch, J.; Gong, M.; Sadelain, M.; Heston, W.D. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. 2001, 21, 249-261. (Pubitemid 32959364)
4. Wright, G.L., Jr.; Grob, B.M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P.F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48, 326-334. (Pubitemid 26279634)
5. Bostwick, D.G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82, 2256-2261. (Pubitemid 28240834)
6. Troyer, J.K.; Beckett, M.L.; Wright, G.L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62, 552-558.
7. Chang, S.S.; Reuter, V.E.; Heston, W.D.; Bander, N.H.; Grauer, L.S.; Gaudin, P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumorassociated neovasculature. Cancer Res. 1999, 59, 3192-3198. (Pubitemid 29316022)
8. Carter, R.E.; Feldman, A.R.; Coyle, J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. U SA 1996, 93, 749-753. (Pubitemid 26041162)
9. Pinto, J.T.; Suffoletto, B.P.; Berzin, T.M.; Qiao, C.H.; Lin, S.; Tong, W.P.; May, F.; Mukherjee, B.; Heston, W.D. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 1996, 2, 1445-1451. (Pubitemid 126447436)
10. Jackson, P.F.; Tays, K.L.; Maclin, K.M.; Ko, Y.S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X.C.; Wozniak, K.; Slusher, B.S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J. Med. Chem. 2001, 44, 4170-4175. (Pubitemid 33095323)
11. Kozikowski, A.P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J.H.; Pshenichkin, S.; Wroblewski, J.T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem. 2001, 44, 298-301. (Pubitemid 32113579)
12. Majer, P.; Jackson, P.F.; Delahanty, G.; Grella, B.S.; Ko, Y.S.; Li, W.; Liu, Q.; Maclin, K.M.; Polakova, J.; Shaffer, K.A.; Stoermer, D.; Vitharana, D.; Wang, E.Y.; Zakrzewski, A.; Rojas, C.; Slusher, B.S.; Wozniak, K.M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiolbased inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem. 2003, 46, 1989-1996. (Pubitemid 36532241)
13. Slusher, B.S.; Vornov, J.J.; Thomas, A.G.; Hurn, P.D.; Harukuni, I.; Bhardwaj, A.; Traystman, R.J.; Robinson, M.B.; Britton, P.; Lu, X.C.; Tortella, F.C.; Wozniak, K.M.; Yudkoff, M.; Potter, B.M.; Jackson, P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 1999, 5, 1396-1402.
14. Tang, H.; Brown, M.; Ye, Y.; Huang, G.; Zhang, Y.; Wang, Y.; Zhai, H.; Chen, X.; Shen, T.Y.; Tenniswood, M. Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem. Biophys. Res. Commun. 2003, 307, 8-14. (Pubitemid 36808529)
15. Banerjee, S.R.; Foss, C.A.; Castanares, M.; Mease, R.C.; Byun, Y.; Fox, J.J.; Hilton, J.; Lupold, S.E.; Kozikowski, A.P.; Pomper, M.G. Synthesis and evaluation of technetium-99m- and rheniumlabeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem. 2008, 51, 4504-4517.
16. Chandran, S.S.; Banerjee, S.R.; Mease, R.C.; Pomper, M.G.; Denmeade, S.R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther. 2008, 7, 974-982.
17. Chen, Y.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J.J.; Castanares, M.; Lupold, S.E.; Babich, J.W.;Mease, R.C.; Pomper, M.G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J. Med. Chem. 2008, 51, 7933-7943.
18. Foss, C.A.; Mease, R.C.; Fan, H.; Wang, Y.; Ravert, H.T.; Dannals, R.F.; Olszewski, R.T.; Heston, W.D.; Kozikowski, A.P.; Pomper, M.G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 2005, 11, 4022-4028. (Pubitemid 40791565)
19. Hillier, S.M.; Maresca, K.P.; Femia, F.J.; Marquis, J.C.; Foss, C.A.; Nguyen, N.; Zimmerman, C.N.; Barrett, J.A.; Eckelman, W.C.; Pomper, M.G.; Joyal, J.L.; Babich, J.W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specificmembrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009, 69, 6932-6940.
20. Mease, R.C.; Dusich, C.L.; Foss, C.A.; Ravert, H.T.; Dannals, R.F.; Seidel, J.; Prideaux, A.; Fox, J.J.; Sgouros, G.; Kozikowski, A.P.; Pomper, M.G. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res. 2008, 14, 3036-3043.
21. Cramer, H.; Okicki, J.R.; Rho, T.; Wang, X.; Silverman, R.H.; Heston, W.D. 2-5A ligands-a new concept for the treatment of prostate cancer. Nucleosides Nucleotides Nucleic Acids 2007, 26, 1471-1477. (Pubitemid 350240714)
22. Davis, M.I.; Bennett, M.J.; Thomas, L.M.; Bjorkman, P.J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. USA 2005, 102, 5981-5986. (Pubitemid 40594241)
23. Mesters, J.R.; Henning, K.; Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr. D Biol. Crystallogr. 2007, 63, 508-513. (Pubitemid 46465946)
24. Hlouchova, K.; Barinka, C.; Konvalinka, J.; Lubkowski, J. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. Febs J. 2009, 276, 4448-4462.
25. Barinka, C.; Byun, Y.; Dusich, C.L.; Banerjee, S.R.; Chen, Y.; Castanares, M.; Kozikowski, A.P.; Mease, R.C.; Pomper, M.G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem. 2008, 51, 7737-7743.
26. Barinka, C.; Hlouchova, K.; Rovenska, M.; Majer, P.; Dauter, M.; Hin, N.; Ko, Y.S.; Tsukamoto, T.; Slusher, B.S.; Konvalinka, J.; Lubkowski, J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J. Mol. Biol. 2008, 376, 1438-1450.
27. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B.S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J. Med. Chem. 2007, 50, 3267-3273. (Pubitemid 47065975)
28. Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J. A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007, 63, 150-153. (Pubitemid 46438673)
29. Mesters, J.R.; Barinka, C.; Li,W.; Tsukamoto, T.;Majer, P.; Slusher, B.S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo J. 2006, 25, 1375-1384.
30. Kularatne, S.A.;Wang, K.; Santhapuram,H.K.; Low, P.S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 2009, 6, 780-789.
31. Maung, J.; Mallari, J.P.; Girtsman, T.A.; Wu, L.Y.; Rowley, J.A.; Santiago, N.M.; Brunelle, A.N.; Berkman, C.E. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg. Med. Chem. 2004, 12, 4969-4979. (Pubitemid 39164405)
32. Kuhnast, B.; Dolle, F.; Terrazzino, S.; Rousseau, B.; Loc'h, C.; Vaufrey, F.; Hinnen, F.; Doignon, I.; Pillon, F.; David, C.; Crouzel, C.; Tavitian, B. General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. Bioconjug. Chem. 2000, 11, 627-636.